IN8bio receives Nasdaq minimum bid price deficiency notice; Q2 net loss $8.6M, cash $10.2M

IN8BIO, INC.

Nasdaq notified IN8bio on Aug 6, 2024 that bid price closed below $1.00 for 31 consecutive days; 180-day compliance period to Feb 3, 2025.
Q2 2024 net loss of $8.6M ($0.19 per share) vs net loss of $7.7M ($0.27) in Q2 2023.
Cash and cash equivalents totaled $10.2M as of June 30, 2024, down from $21.3M at Dec 31, 2023.
Phase 1 INB-100 data: 100% 1-year complete remission in evaluable patients; two patients relapse-free over 3.5 years.
Phase 1 INB-200: 92% of GBM patients exceeded median PFS of 7 months; no cell therapy-related toxicities observed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.